RAUTENSIN Drug Patent Profile
When do Rautensin patents expire, and when can generic versions of Rautensin launch?
Rautensin is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in RAUTENSIN is alseroxylon. There is one drug master file entry for this compound. Additional details are available on the alseroxylon profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RAUTENSIN?
- What are the global sales for RAUTENSIN?
- What is Average Wholesale Price for RAUTENSIN?
Summary for RAUTENSIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 4,079 |
| DailyMed Link: | RAUTENSIN at DailyMed |
US Patents and Regulatory Information for RAUTENSIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | RAUTENSIN | alseroxylon | TABLET;ORAL | 009215-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
